Reconstitute with 20mM Tris and 150mM NaCl to 0.1-1.0mg/ml. Do not vortex. Lyophilized from 20mM Tris, 150mM NaCl, 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose, ProClin 300.
Expression System:
E. coli
Form:
Lyophilized powder
Sequence:
N-terminal His-Tag, Gly4~Lys216 (NP_005108.1)
Application Notes:
Fibroblast Growth Factor 19 (FGF19) is a member of the fibroblast growth factor (FGF) family. FGF19 has important roles as a hormone produced in the ileum in response to bile acid absorption, regulates new bile acid synthesis, acting through the FGFR4/Klotho-beta receptor complexes in the liver to inhibit CYP7A1. FGF19 also has metabolic effects, affecting glucose and lipid metabolism. Besides, Fibroblast Growth Factor Receptor 1 (FGFR1) has been identified as an interactor of FGF19, thus a binding ELISA assay was conducted to detect the interaction of recombinant human FGF19 and recombinant human FGFR1. Briefly, FGF19 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to FGFR1-coated microtiter wells and incubated for 2h at 37C. Wells were washed with PBST and incubated for 1h with anti-FGF19 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37C. Finally, add 50 µl stop solution to the wells and read at 450nm immediately. The binding activity of FGF19 and FGFR1 was in a dose dependent manner.
* VAT and and shipping costs not included. Errors and price changes excepted
